Correction: Tumour-reactive T cell subsets in the microenvironment of ovarian cancer.

Journal

British journal of cancer
ISSN: 1532-1827
Titre abrégé: Br J Cancer
Pays: England
ID NLM: 0370635

Informations de publication

Date de publication:
Apr 2019
Historique:
pubmed: 21 3 2019
medline: 21 3 2019
entrez: 21 3 2019
Statut: ppublish

Résumé

Since the publication of this paper, the authors noticed that the funding information was not complete. The correct funding information is now shown in the Acknowledgements section. Acknowledgements The studies were supported by grants from the OvaCure Foundation, the Danish Cancer Society Research Foundation, the Anticancer Fund, Aase og Ejnar Danielsens Foundation and the Independent Research Fund Denmark (grant number DFF-4183-00597).

Identifiants

DOI: 10.1038/s41416-019-0425-6 PMID: 30890776 PMC: PMC6474273
pubmed: 30890776
doi: 10.1038/s41416-019-0425-6
pii: 10.1038/s41416-019-0425-6
pmc: PMC6474273
doi:

Types de publication

Published Erratum

Langues

eng

Pagination

870

Commentaires et corrections

Type : ErratumFor

Auteurs

Marie Christine Wulff Westergaard (MCW)

Center for Cancer Immune Therapy, Department of Hematology, Herlev Hospital, University of Copenhagen, Copenhagen, Denmark.

Rikke Andersen (R)

Center for Cancer Immune Therapy, Department of Hematology, Herlev Hospital, University of Copenhagen, Copenhagen, Denmark.
Department of Oncology, Herlev Hospital, University of Copenhagen, Copenhagen, Denmark.

Chloé Chong (C)

Ludwig Institute for Cancer Research, University of Lausanne, Lausanne, Switzerland.
Department of Oncology, University Hospital of Lausanne, Lausanne, Switzerland.

Julie Westerlin Kjeldsen (JW)

Center for Cancer Immune Therapy, Department of Hematology, Herlev Hospital, University of Copenhagen, Copenhagen, Denmark.
Department of Oncology, Herlev Hospital, University of Copenhagen, Copenhagen, Denmark.

Magnus Pedersen (M)

Center for Cancer Immune Therapy, Department of Hematology, Herlev Hospital, University of Copenhagen, Copenhagen, Denmark.
Department of Oncology, Herlev Hospital, University of Copenhagen, Copenhagen, Denmark.

Christina Friese (C)

Center for Cancer Immune Therapy, Department of Hematology, Herlev Hospital, University of Copenhagen, Copenhagen, Denmark.

Thomas Hasselager (T)

Department of Pathology, Herlev Hospital, University of Copenhagen, Copenhagen, Denmark.

Henrik Lajer (H)

Department of Gynaecology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.

George Coukos (G)

Ludwig Institute for Cancer Research, University of Lausanne, Lausanne, Switzerland.
Department of Oncology, University Hospital of Lausanne, Lausanne, Switzerland.

Michal Bassani-Sternberg (M)

Ludwig Institute for Cancer Research, University of Lausanne, Lausanne, Switzerland.
Department of Oncology, University Hospital of Lausanne, Lausanne, Switzerland.

Marco Donia (M)

Center for Cancer Immune Therapy, Department of Hematology, Herlev Hospital, University of Copenhagen, Copenhagen, Denmark.
Department of Oncology, Herlev Hospital, University of Copenhagen, Copenhagen, Denmark.

Inge Marie Svane (IM)

Center for Cancer Immune Therapy, Department of Hematology, Herlev Hospital, University of Copenhagen, Copenhagen, Denmark. inge.marie.svane@regionh.dk.
Department of Oncology, Herlev Hospital, University of Copenhagen, Copenhagen, Denmark. inge.marie.svane@regionh.dk.

Classifications MeSH